Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats

References

• Gardos G, Cole JO. The treatment of tardive dyskinesia. In: Bloom FE, Kupfer DJ, (eds.) Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995. p. 1503–11.
   Google Scholar
• Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(Suppl. 11):40–5.
   PubMed Web of Science ®Google Scholar
• Subramaniam B, Rollema H, Woolf T, Castagnoli NG. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 1990;166:238–44. doi: 10.1016/0006-291X(90)91936-M
   PubMed Web of Science ®Google Scholar
• Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998;71:1002–12. doi: 10.1046/j.1471-4159.1998.71031002.x
   PubMed Web of Science ®Google Scholar
• Andreassen AO, Jørgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesia in rats. Prog Neurobiol 2000;61:525–41. doi: 10.1016/S0301-0082(99)00064-7
   PubMed Web of Science ®Google Scholar
• Pall HS, Williams AC, Blake DR, Lunec J. Evidence of enhanced lipid peroxidation in the cerebrospinal fluid of patients taking phenothiazines. Lancet 1987;2:596–9. doi: 10.1016/S0140-6736(87)92987-4
   PubMed Web of Science ®Google Scholar
• Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radicals activity in cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990;28:535–9. doi: 10.1016/0006-3223(90)90490-S
   PubMed Web of Science ®Google Scholar
• Adler LA, Paselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993;150:1405–7. doi: 10.1176/ajp.150.9.1405
   PubMed Web of Science ®Google Scholar
• Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 2006;10(4):515–31. doi: 10.1517/14728222.10.4.515
   PubMed Web of Science ®Google Scholar
• Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ. Increased dopamine D2 receptor binding after long-term treatment with anti-psychotics in humans: a clinical PET study. Psychopharmacol Berl 2000;152(2):174–80. doi: 10.1007/s002130000532
   PubMed Web of Science ®Google Scholar
• Moosmann B, Behl C. Dietary phenols: antioxidants for the brain? Nutr Neurosci 2000;3(1):1–10. doi: 10.1080/1028415X.2000.11747298
   PubMed Web of Science ®Google Scholar
• Thaakur S, Himabindhu G. Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats. J Neural Transm 2009;116(7):807–14. doi: 10.1007/s00702-009-0232-y
   PubMed Web of Science ®Google Scholar
• Bishnoi M, Chopra K, Kulkarni SK. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes. Fundam Clin Pharmacol 2007;21(5):521–9. doi: 10.1111/j.1472-8206.2007.00512.x
   PubMed Web of Science ®Google Scholar
• Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58:1049–52. doi: 10.1001/archpsyc.58.11.1049
   PubMed Web of Science ®Google Scholar
• Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72(5):615–21. doi: 10.4088/JCP.09m05125yel
   PubMed Web of Science ®Google Scholar
• Lister J, Nobrega JN, Fletcher PJ, Remington G. Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies. Psychopharmacology 2014;231:2237–49. doi: 10.1007/s00213-014-3582-6
   PubMed Web of Science ®Google Scholar
• Garg A, Garg S, Zaneveld LJ, Singla AK. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. Phytother Res 2001;15:655–69. doi: 10.1002/ptr.1074
   PubMed Web of Science ®Google Scholar
• Vaeth A. Phloretin Acute Oral Toxicity Study in the Rat. Frey-tox, Germany. Lab no. 02809. 2006 April 24. Unpublished report submitted by EFFA to FLAVIS Secretariat.
   Google Scholar
• Flavouring Group Evaluation 32 (FGE.32): flavonoids (Flavanones and dihydrochalcones) from chemical groups 25 and 30. EFSA panel on food contact materials, enzymes, flavourings and processing aids. EFSA (European Food Safety Authority) J 2010;8(9):1065–126.
   Google Scholar
• Brand W, Boersma MG, Bik H, Hoek-van den Hil EF, Vervoort J, Barron D, et al. Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples. Drug Metab Dispos 2010;38(4):617–25. doi: 10.1124/dmd.109.031047
   PubMed Web of Science ®Google Scholar
• Giménez-Bastida JA, González-Sarrías A, Vallejo F, Espín JC, Tomás-Barberán FA. Hesperetin and its sulfate and glucuronide metabolites inhibit TNF-α induced human aortic endothelial cell migration and decrease plasminogen activator inhibitor-1 (PAI-1) levels. Food Funct 2016;7(1):118–26. doi: 10.1039/C5FO00771B
   PubMed Web of Science ®Google Scholar
• Cho J. Antioxidant and neuroprotective effects of hesperedin and its aglycone hesperetin. Arch Pharm Res 2006;29(8):699–706. doi: 10.1007/BF02968255
   PubMed Web of Science ®Google Scholar
• Choi EJ, Ahn WS. Neuroprotective effects of chronic hesperetin administration in mice. Arch Pharm Res 2008;31(11):1457–62. doi: 10.1007/s12272-001-2130-1
   PubMed Web of Science ®Google Scholar
• Roghani K, Baluchnejadmojarad H. The effect of hesperetin on short-term spatial memory and passive avoidance learning and memory in diabetic rats. Arak Medical Univ J 2011;14(1):46–54.
   Google Scholar
• Baluchnejadmojarad T, Roghani M. The flavonoid hesperetin alleviates behavioral abnormality in 6-hydroxydopamine rat model of hemi-Parkinsonism. Basic Clin Neurosci 2014;8(22):20–3.
   Google Scholar
• Dimpfel W. Different anticonvulsive effects of hesperidin and its aglycone hesperetin on electrical activity in the rat hippocampus in-vitro. J Pharm Pharmacol 2006;58:375–9. doi: 10.1211/jpp.58.3.0012
   PubMed Web of Science ®Google Scholar
• Huang SM, Tsai SY, Lin JA, Wu CH, Yen GC. Cytoprotective effects of hesperetin and hesperidin against amyloid β-induced impairment of glucose transport through downregulation of neuronal autophagy. Mol Nutr Food Res 2012;56:601–9. doi: 10.1002/mnfr.201100682
   PubMed Web of Science ®Google Scholar
• Jin YR, Han XH, Zhang YH, Lee JJ, Limb Y, Chung JH, et al. Antiplatelet activity of hesperetin. Atherosclerosis 2006;194:144–52. doi: 10.1016/j.atherosclerosis.2006.10.011
   PubMed Web of Science ®Google Scholar
• Choi EM, Lee YS. Effects of hesperetin on the production of inflammatory mediators in IL-1beta treated human synovial cells. Cell Immunol 2010;264(1):1–3. doi: 10.1016/j.cellimm.2010.05.006
   PubMed Web of Science ®Google Scholar
• Trivedi PP, Kushwaha S, Tripathi DN, Jena GB. Cardioprotective effects of hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat. Cardiovasc Toxicol 2011;11:215–25. doi: 10.1007/s12012-011-9114-2
   PubMed Web of Science ®Google Scholar
• Gordon JH, Borison RL, Diamond BI. Estrogen in experimental tardive dyskinesia. Neurology 1980;30(5):551–4. doi: 10.1212/WNL.30.5.551
   PubMed Web of Science ®Google Scholar
• Bishnoi M, Chopra K, Kulkarni SK. Protective effect of curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav 2008;88:511–22. doi: 10.1016/j.pbb.2007.10.009
   PubMed Web of Science ®Google Scholar
• Dhingra D, Gahalain N. Amelioration of haloperidol-induced orofacial dyskinesia and catalepsy by ellagic acid in rats. Int J Res Ayurveda Pharm 2016;7(Suppl. 2):222–7. doi: 10.7897/2277-4343.07292
   Google Scholar
• Kulkarni SK. Practical pharmacology and clinical pharmacy. Delhi: Vallabh Prakashan; 2008.
   Google Scholar
• Naidu PS, Singh A, Kulkarni SK. Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin. Pharmacology 2004;70(2):59–67. doi: 10.1159/000074669
   PubMed Web of Science ®Google Scholar
• Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–8. doi: 10.1016/0003-2697(79)90738-3
   PubMed Web of Science ®Google Scholar
• Ellman GL. Tissue sulfhydryl groups. Arch Biochem-Biophys 1959;82:70–7. doi: 10.1016/0003-9861(59)90090-6
   PubMed Web of Science ®Google Scholar
• Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949;177(2):751–66.
   PubMed Web of Science ®Google Scholar
• Aebi H. Catalase. Meth Enzymol 1984;105:121–6. doi: 10.1016/S0076-6879(84)05016-3
   PubMed Web of Science ®Google Scholar
• Kono Y. Generation of superoxide radical during autooxidation of hydroxylamine and an assay of superoxide dismutase. Arch Biochem Biophys 1978;186:189–95. doi: 10.1016/0003-9861(78)90479-4
   PubMed Web of Science ®Google Scholar
• Schlumpf M, Lichtensteiger W, Langemann H, Waser PG, Hefti F. A fluorimetric micromethod for the simultaneous determination of serotonin, noradrenaline and dopamine in milligram amount of brain tissue. Biochem Pharmacol 1974;23:2437–46. doi: 10.1016/0006-2952(74)90235-4
   PubMed Web of Science ®Google Scholar
• Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci 1986;9:107–8. doi: 10.1016/0166-2236(86)90035-4
   Web of Science ®Google Scholar
• Sanberg PR. Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 1980;284(5755):472–3. doi: 10.1038/284472a0
   PubMed Web of Science ®Google Scholar
• Sanberg PR, Bunsey MD, Giordano M, Norman AB. The catalepsy test: its ups and downs. Behav Neurosci 1988;102(5):748–59. doi: 10.1037/0735-7044.102.5.748
   PubMed Web of Science ®Google Scholar
• Storey VJ, Middlemiss DN, Reavill C. Effect of haloperidol and (-) – sulpiride on dopamine agonist-induced hypoactivity. Neuropharmacology 1995;34(4):449–55. doi: 10.1016/0028-3908(95)00010-4
   PubMed Web of Science ®Google Scholar
• Naidu PS, Kulkarni SK. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol 2001;428:81–6. doi: 10.1016/S0014-2999(01)01284-5
   PubMed Web of Science ®Google Scholar
• Parikh V, Khan MM, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003;37:43–51. doi: 10.1016/S0022-3956(02)00048-1
   PubMed Web of Science ®Google Scholar
• Peet M, Langharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peroxidation and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993;8:151–3. doi: 10.1097/00004850-199300830-00003
   PubMed Web of Science ®Google Scholar
• Bishnoi M, Kumar A, Chopra K, Kulkarni SK. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia. Indian J Exp Biol 2007;45(2):175–9.
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Naidu PS. Tardive dyskinesia: an update. Drugs Today 2001;37:97–119. doi: 10.1358/dot.2001.37.2.834327
   PubMed Web of Science ®Google Scholar
• Sandyk R, Fisher H. Serotonin in involuntary movement disorders. Int J Neurosci 1988;42:185–205. doi: 10.3109/00207458808991596
   PubMed Web of Science ®Google Scholar